645.660 Million USD
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Zacks Investment Research 11:17 17/11/2022
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
CareDx (CDNA) appears to have found support after losing some va...
Zacks Investment Research 11:18 11/11/2022
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CareDx (CDNA) is technically in oversold territory now, so the h...
Seeking Alpha 22:52 03/11/2022
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q3 2022 Earnings Conference Call Nove...
Seeking Alpha 12:41 18/10/2022
CareDx: Shaking Off First-Mover Disadvantage
The introduction of new products and the further extension of re...